Maxim Group Releases a Buy Rating on Omeros Corp

By Ryan Adsit

In a report released today, Jason Kolbert from Maxim Group reiterated a Buy rating on Omeros Corp (NASDAQ: OMER), with a price target of $22. The company’s shares closed yesterday at $11.60.

According to, Kolbert is ranked 0 out of 5 stars with an average return of -12.3% and a 32.6% success rate. Kolbert covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, ContraVir Pharmaceuticals Inc, and Brainstorm Cell Therapeutics.

Currently, the analyst consensus on Omeros Corp is Strong Buy and the average price target is $47, representing a 305.2% upside.

In a report released today, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $21 price target.

The company has a one year high of $16.38 and a one year low of $7.20. Currently, Omeros Corp has an average volume of 364.3K.

Based on the recent corporate insider activity of 13 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of OMER in relation to earlier this year. Most recently, in October 2016, Marcia Kelbon, the VP Patent and General Counsel of OMER bought 3,004 shares for a total of $18,174.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Omeros Corp. operates as a biopharmaceutical company committed to discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.